Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT07661121

EMVITAL + EMFACE Combination Therapy for Temporomandibular Joint (TMJ) Pain Relief

This prospective, multi-center, open-label, single-arm clinical study will evaluate the efficacy and performance of the BTL-043 and BTL-785F devices for alleviating TMJ pain. Up to 60 subjects will undergo four treatment visits, administered 2-10 days apart, followed by 1-month and 3-month follow-up visits. During a single treatment session at each visit, subjects will receive consecutive treatment with both devices. At baseline, informed consent, eligibility assessment, Fitzpatrick phototype evaluation, TMD Disability Index, VAS, weight and height measurements, 2D mandibular ROM photographs, and mandibular/lateral ROM assessments will be completed. A urine pregnancy test will be performed prior to each treatment visit. After the final treatment, subjects will complete the TCQ, SSQ & QoL, TMD Disability Index, and VAS, and repeat all physical assessments. At both follow-up visits, subjects will complete the SSQ & QoL, TMD Disability Index, and VAS, and repeat the physical assessments. Safety will be evaluated through documentation and assessment of adverse events at each treatment and follow-up visit.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Key information

Conditions

Temporomandibular Disorder (TMD) Craniomandibular Disorders Facial Pain Jaw Diseases Joint Diseases Mandibular Diseases Muscular Diseases Musculoskeletal Diseases Neck Pain Neurologic Manifestations Pain Pathological Conditions, Signs and Symptoms Signs and Symptoms Stomatognathic Diseases Temporomandibular Joint Disorders Temporomandibular Joint Pain

Age range

22 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

The Dental Touch, Leesburg, Florida, United States

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 22 years and older
  • Voluntarily signed an informed consent form
  • Subject is willing to comply with study instructions, to return to the clinic for the required visits
  • Willingness to adhere to and continue current pain management plan
  • Subjects willing and able to maintain their regular (pre-procedure) diet, exercise and therapy regimen without significant change during study participation
  • Subject is willing and able to abstain from partaking in any new treatments other than this study procedure to treat TMJ pain
  • Women of child-bearing potential* are required to use birth control measures during the whole duration of the study
  • Women of childbearing potential are defined as any female who has experienced menarche and who is NOT permanently sterile or postmenopausal. Postmenopausal is defined as 12 consecutive months with no menses without an alternative medical cause.

Exclusion criteria

  • Major systemic diseases - e.g., uncontrolled Diabetes mellitus, systemic lupus erythematosus
  • Current pregnancy, nursing, or IVF procedure
  • Photosensitivity, medications affecting sensitivity to light
  • Tattoos or other higher pigmented regions in the treated area
  • Corticosteroids or injections of the treated area within the last 3 months, long-term corticosteroids use
  • Anticoagulant therapy, bleeding disorders
  • Hemorrhage in the treated area
  • Application over the thyroid or other endocrine glands
  • Subjects currently undergoing, or who have received, radiation therapy or chemotherapy within the past 6 months prior to study treatment
  • Known or suspected malignancy, history of cancer, any type of malignancy or pre-malignant moles
  • Febrile conditions, serious illness, chronic infection
  • Neurological disorders (such as multiple cerebrospinal sclerosis, epilepsy)
  • Sensory or sensitivity disorders in the treatment area
  • Active bacterial or viral infection, acute inflammation
  • Impaired immune system
  • Isotretinoin in the past 12 months
  • Skin-related autoimmune diseases
  • Poor healing and unhealed wounds in the treatment area
  • Metal implants near the treatment area or neutral electrode
  • Permanent implant near the treatment area
  • Pacemaker or internal defibrillator, or any other active electrical implant, anywhere in the body
  • Active collagen diseases
  • Cardiovascular diseases (such as vascular diseases, peripheral arterial disease, thrombophlebitis and thrombosis)
  • Any active condition in the treatment area, such as sores, psoriasis, eczema, rash and rosacea
  • Any surgical procedure in the treatment area within the last three months or before complete healing
  • Tuberculosis
  • Hepatitis
  • Poorly controlled endocrine disorders
  • History of bleeding coagulopathies
  • Acute neuralgia and neuropathy
  • Kidney or liver failure
  • Skin dermabrasion, skin resurfacing, or deep chemical peeling in the treatment area within 3 months prior to the treatment
  • Electroanalgesia without exact diagnose of pain etiology
  • Serious psychopathological disorders (such as schizophrenia)
  • Inflammation of blood or lymphatic vessels
  • Scarring in the treatment area
  • Swollen, infected, or inflamed areas or damaged skin, skin eruptions, e.g., phlebitis, thrombophlebitis, varicose veins, etc.
  • Hypersensitive carotid sinus

Treatment and study plan

Treatment with BTL-043 and BTL-785F

Device

All subjects will receive a consecutive treatment with the BTL-043 and BTL-785F devices during a single visit. Subjects will be required to complete four (4) treatment visits and two (2) follow-up visits conducted at 1 month and 3 months after the last treatment.

Primary outcomes

  1. Change from Baseline in the Temporomandibular Dysfunction (TMD) Disability Index Score at 3 Months

    Time frame: Baseline and 3 months

    The Temporomandibular Dysfunction (TMD) Disability Index is a self-reported questionnaire used to assess the impact of TMJ disorders on a participant's daily activities, such as talking, chewing, and sleeping. The questionnaire consists of 10 categories, each containing 5 statements. Each category is scored on a scale from 0 to 4, where 0 represents no limitation and 4 represents maximum restriction due to pain. The overall score is calculated by summing the scores of all 10 items, resulting in a total possible score ranging from 0 to 40. On this scale, a total score of 0 indicates no disability and 40 indicates extreme disability. A negative change from baseline (a decrease in the total score) indicates a reduction in disability and an improvement in the participant's condition over time.

  2. Change from Baseline in the Visual Analogue Scale (VAS) Pain Score at 3 Months

    Time frame: Baseline and 3 months

    The Visual Analogue Scale (VAS) is a self-reported measure used to assess the intensity of TMJ-related pain experienced by the participants in the treatment area. Participants rate their perceived pain level on a numerical scale ranging from 0 to 10. On this scale, 0 is equivalent to "no pain" and 10 indicates the "worst possible pain". The baseline score is compared to the score collected at the 3-month follow-up visit. A negative change from baseline (a decrease in the VAS score) indicates a reduction in pain intensity and an improvement in the participant's condition over time.

Secondary outcomes

  1. Change from Baseline in Mandibular Range of Motion at 3 Months

    Time frame: Baseline and 3 months

    Mandibular range of motion is measured objectively in millimeters (mm) using a specialized scale. Two measurements are taken: "comfort" (opening the mouth to a comfortable level without pain) and "active" (opening the mouth as wide as possible despite the presence of pain). A positive change from baseline (an increase in the measured mm) indicates an improvement in jaw mobility.

  2. Change from Baseline in Lateral Range of Motion at 3 Months

    Time frame: Baseline and 3 months

    Lateral mandibular range of motion is measured objectively in millimeters (mm) using a specialized scale. Two measurements are taken: left lateral excursion (moving the lower jaw as far as possible to the left) and right lateral excursion (moving the lower jaw as far as possible to the right). A positive change from baseline (an increase in the measured mm) indicates an improvement in lateral jaw mobility.

  3. Subject Satisfaction Assessed by the Subject Satisfaction & Quality of Life Questionnaire

    Time frame: 3 months post treatment

    Subject satisfaction with the treatment outcomes and its impact on quality of life is assessed using a 17-item self-reported questionnaire. Each item is rated on a 5-point Likert scale, where 1 indicates "strongly disagree" and 5 indicates "strongly agree". Higher scores represent greater treatment satisfaction and improvement in the subject's quality of life.

  4. Therapy Comfort Assessed by the Therapy Comfort Questionnaire

    Time frame: Immediately after the final treatment

    Therapy comfort is assessed using a self-reported questionnaire. Participants indicate their overall comfort on a 5-point Likert scale (where 1 is "strongly disagree" and 5 is "strongly agree" with the statement "I found the treatment comfortable"). Additionally, any pain experienced during treatment is rated on a Numerical Analogue Scale ranging from 0 ("no pain") to 10 ("worst possible pain"). Lower pain scores and higher agreement scores indicate greater therapy comfort.

  5. Incidence of Treatment-related Adverse Events

    Time frame: From baseline up to 3 months post-treatment

    Overall safety is evaluated continuously by monitoring, assessing, and recording the occurrence and severity of any adverse events, side effects, or unanticipated problems throughout the course of the study

Sponsors and collaborators

Lead sponsor

BTL Industries Ltd.

Industry

Registry information

Official study title

Evaluating the Safety and Efficacy of the BTL-043 and BTL-785F Devices in Alleviating Temporomandibular Joint (TMJ) Pain

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Jun 22, 2026
Registry last updated
Jun 22, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.